Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

Abstract: The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF-Degrading Conjugate Compound.

Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Abstract: The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF-Degrading Conjugate Compound.

Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Abstract: A magnetic voltage/current limiting system is mounted in conjunction with a main coil, in a coil assembly of a wind turbine generator, for limiting the outputted voltage (or current) to a predetermined upper value. The limiting system generally has at least one limiting coil and a control circuit connected to the main coil. The limiting system is configured to be activated when the voltage (or current) outputted by the main coil increases beyond the predetermined upper value. Once activated, the limiting system diverts a portion of the outputted current to the limiting coil such as to generate a magnetic field in the limiting coil. This additional magnetic field generally limits the amount magnetic field generated by passing magnets to flow through the main coil, thereby limiting the outputted voltage.

Abstract: A magnetic voltage/current limiting system is mounted in conjunction with a main coil, in a coil assembly of a wind turbine generator, for limiting the outputted voltage (or current) to a predetermined upper value. The limiting system generally comprises at least one limiting coil and a control circuit connected to the main coil. The limiting system is configured to be activated when the voltage (or current) outputted by the main coil increases beyond the predetermined upper value. Once activated, the limiting system diverts a portion of the outputted current to the limiting coil such as to generate a magnetic field in the limiting coil. This additional magnetic field generally limits the amount magnetic field generated by passing magnets to flow through the main coil, thereby limiting the outputted voltage.

Abstract: An electric generator for use with a turbine (e.g. wind turbine) is disclosed. The generator comprises a stator and a rotor mounted for rotation with respect to the stator. The rotor comprises an even number M of magnets and the stator comprises an odd number C of coils. The number M of magnets and the number C of coils are chosen such that they do not have a common divider except 1. The coils are also generally made of a large number of turns of small wires such that each coil outputs high voltage but low current. In addition, the output of each one of the coils is generally rectified individually. An electric generator assembly is also disclosed. The generator of the invention is connected to a turbine, preferably a wind turbine, for rotating the rotor of the generator. A method for producing electricity is also disclosed.

Abstract: A magnetic voltage/current limiting system is mounted in conjunction with a main coil, in a coil assembly of a wind turbine generator, for limiting the outputted voltage (or current) to a predetermined upper value. The limiting system generally comprises at least one limiting coil and a control circuit connected to the main coil. The limiting system is configured to be activated when the voltage (or current) outputted by the main coil increases beyond the predetermined upper value. Once activated, the limiting system diverts a portion of the outputted current to the limiting coil such as to generate a magnetic field in the limiting coil. This additional magnetic field generally limits the amount magnetic field generated by passing magnets to flow through the main coil, thereby limiting the outputted voltage.

Abstract: A length of conduit for encasing at least one electrical wire or cable, comprising two or more longitudinal conduit sections. Each longitudinal conduit section has two longitudinal edges formed with interlocking edge profiles shaped to engage with a snap fit with opposing longitudinal edge profiles of one or more other longitudinal conduit sections to form the conduit. Each conduit section also has one or more tabs or slots along the longitudinal edges to mate with tabs or slots on the other longitudinal conduit sections when brought together, to thereby substantially prevent relative longitudinal movement of the conduit sections. A longitudinal conduit section for use in forming the length of conduit is also described, which can be cut into two or more longitudinal conduit sub-sections and the sub-sections can be engaged to one another with a snap fit along the interlocking edge profiles to form a conduit.

Abstract: A concentrated solution of a wound healing promoter, in particular fibronectin, is used to develop solid wound dressings. The solid wound dressings containing fibronectin are easy to apply, easy to remove, and deliver fibronectin in a range of physiologically active dosages.

Abstract: This invention relates to the production of topical dosage forms containing human plasma fibronectin in combination with growth factors having human mitogenic or angiogenic activity, such as platelet-derived growth factor (PDGF-&bgr;&bgr;), to promote wound healing in humans.

Abstract: Aqueous, non-buffered solutions containing high concentrations of fibronectin and other wound healing promoters are produced, which can then be used to make topical gel and cream formulations with high concentrations of these wound healing promoters. The formulations are used for the healing of cutaneous wounds. The formulations provide slow release and increased contact time of fibronectin and of other wound healing promoters to the wound site leading to effective absorption of the promoters.

Abstract: A deepithelialized skin cell diffusion system which can be used to select topical and cream formulations containing wound healing promoters such as plasma fibronectin. The formulations provide slow release and increased contact time of fibronectin or other wound healing promoters to the wound site leading to its effective absorption.

Abstract: Aqueous, non-buffered solutions containing high concentrations of fibronectin and other wound healing promoters are produced, which can then be used to make topical gel and cream formulations with high concentrations wound healing promoters. The formulations arc used for the healing of cutaneous wounds. The formulations provide slow release and increased contact time of fibronectin and of other wound healing promoters to the wound site leading to the effective absorption of the promoters.

Abstract: A deepithelialized skin cell diffusion system which can be used to select topical gel and cream formulations containing human other wound healing promoters such as plasma fibronectin. The formulations provide slow release and increased contact time of fibronectin or other wound healing promoters to the wound site leading to its effective absorption.

Abstract: A deepithelialized skin cell diffusion system which can be used to select topical gel and cream formulations containing human other wound healing promoters such as plasma fibronectin. The formulations provide slow release and increased contact time of fibronectin or other wound healing promoters to the wound site leading to its effective absorption.